CoChat
Sign Up
Cited by 553

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Steelman, Linda S., Chappell, William H., Abrams, Stephen L., Kempf, C. Ruth, Long, Jacquelyn, Laidler, Piotr, Mijatovic, Sanja, Maksimovic-Ivanic, Danijela, Stivala, Franca, Mazzarino, Maria C., Donia, Marco, Fagone, Paolo, Malaponte, Graziella, Nicoletti, Ferdinando, Libra, Massimo, Milella, Michele, Tafuri, Agostino, Bonati, Antonio, Bäsecke, Jörg, Cocco, Lucio, Evangelisti, Camilla, Martelli, Alberto M., Montalto, Giuseppe, Cervello, Melchiorre, McCubrey, James A.·2011·Aging
DOI 10.18632/aging.100296PMC PMC3091517
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/aging.100296

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fine-tuning of MEK/ERK pathway activation by natural bioactive compounds, such as flavonoids, appears to promote physiological responses of gene transcription/translation and cell growth/survival and, in turn, advance human health as neuroprotectants and cognitive enhancers.

    “Although sustained hyperactivation of MEK/ERK signaling is a prerequisite for malignant transformation or progression, the fine-tuning of this pathway activation by natural bioactive compounds, such as flavonoids, appears to promote physiological responses of gene transcription/translation and cell growth/survival and, in turn, advance human health as neuroprotectants and cognitive enhancers.48–51”

    From TERT activation targets DNA methylation and multiple aging hallmarks (2024) · cites this paper as [48]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 230

  1. Crespo, 2009, ERK dimmers and scaffold proteins: unexpected partners for a forgotten task, Cell Cycle, 8, 1007, 10.4161/cc.8.7.8078 · DOI
  2. Basecke, 2008, Targeting Survival Cascades Induced by Activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy, Leukemia, 2, 708
  3. Ove, 2009, Emerging Raf Inhibitors, Exp Opin Emerging Drugs, 1, 633
  4. McCubrey, 2010, The emerging role of the phosphatiylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogensis, Biochim Biophys Act, 180, 991
  5. Bakin, 2009, Ras alters epithelial-mesenchymal transition in response to TGFbeta by reducing actin fibers and cell-matrix adhesion, Cell Cycle, 8, 284, 10.4161/cc.8.2.7590 · DOI
  6. Downward, 2003, Targeting Ras signaling pathways in cancer therapy, Nature Reviews Cancer, 3, 11, 10.1038/nrc969 · DOI
  7. Sobue, 2004, Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells, J Biol Chem, 27, 40807
  8. Marshall, 1995, Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation, EMBO J, 1, 3136
  9. Lenormand, 2009, Total ERK1/2 activity regulates cell proliferation, Cell Cycle, 8, 705, 10.4161/cc.8.5.7734 · DOI
  10. Bartek, 2008, Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay, Cell Cycle, 7, 2553, 10.4161/cc.7.16.6442 · DOI
  11. Tesfaigzi, 2009, How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?, Cell Cycle, 8, 1168, 10.4161/cc.8.8.8147 · DOI
  12. Greenberg, 1996, Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase, Science, 27, 959
  13. Tzivion, 2006, Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase, Mol Biol Cell, 1, 1141
  14. Morrison, 2005, Regulation of Raf-1 by direct feedback phosphorylation, Mol Cell, 1, 215
  15. Misawa, 2003, Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf, Oncogene, 2, 8823
  16. Baccarini, 2009, A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal, Nat Struct Mol Biol, 1, 294
  17. Davis, 1995, Transcriptional regulation by MAP kinases, Mol Reprod Dev, 4, 459, 10.1002/mrd.1080420414 · DOI
  18. McCubrey, 2010, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients, Oncotarget, 1, 89, 10.18632/oncotarget.114 · DOI
  19. Vogt, 2010, Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS, Cell Cycle, 9, 596, 10.4161/cc.9.3.10599 · DOI
  20. Toker, 1997, Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate, Science, 27, 665
  21. Woodgett, 1991, Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families, Eur J Biochem, 20, 475
  22. Cohen, 1997, Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha, Curr Biol, 7, 261, 10.1016/S0960-9822(06)00122-9 · DOI
  23. McCubrey, 2008, Akt Inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells, Cell Cycle, 7, 631, 10.4161/cc.7.5.5416 · DOI
  24. Montminy, 1998, CREB is a regulatory target for the protein kinase Akt/PKB, J Biol Chem, 27, 32377
  25. Cantrell, 1997, Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F, Immunity, 7, 679, 10.1016/S1074-7613(00)80388-X · DOI
  26. Weiss, 1999, Induction of NF-kappaB by the Akt/PKB kinase, Curr Biol, 9, 601, 10.1016/S0960-9822(99)80265-6 · DOI
  27. Coffer, 2009, The role of the PI3K-PKB signaling module in regulation of hematopoiesis, Cell Cycle, 8, 560, 10.4161/cc.8.4.7654 · DOI
  28. Nuñez, 1997, Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt, Science, 27, 687
  29. Baker, 2009, PTEN and the PI3-kinase pathway in cancer, Ann Rev Pathol Mech Dis, 4, 127, 10.1146/annurev.pathol.4.110807.092311 · DOI
  30. Abu-Baker, 2009, The Par-4/PTEN connection in tumor suppression, Cell Cycle, 8, 2518, 10.4161/cc.8.16.9384 · DOI
  31. Choudhury, 2004, Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase, J Biol Chem, 27, 15258
  32. Feng, 2009, Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair, Cell Cycle, 8, 2198, 10.4161/cc.8.14.8947 · DOI
  33. Mijatovic, 2011, Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways, J Cell Physiol
  34. Barata, 2008, PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability, J Clin Invest, 11, 3762
  35. Newton, 2005, PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth, Mol Cell, 1, 13
  36. Krystal, 1996, The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triposphate 5-phosphatase, Proc Natl Acad Sci USA, 9, 1689
  37. Erneux, 1999, Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells, Biochem J, 34, 697
  38. Stokoe, 2000, 5′phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells, Mol Cell Biol, 2, 6860
  39. Goncharova, 2009, PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects, Cell Cycle, 8, 403, 10.4161/cc.8.3.7555 · DOI
  40. Menendez, 2009, AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor, Cell Cycle, 8, 3679, 10.4161/cc.8.22.9905 · DOI
  41. Bouscary, 2009, Targeting translation in acute myeloid leukemia: a new paradigm for therapy?, Cell Cycle, 8, 3893, 10.4161/cc.8.23.10091 · DOI
  42. Tamanoi, 2009, Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein, J Biol Chem, 28, 12783
  43. Nardella, 2008, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J Clin Invest, 11, 3065
  44. Mueckler, 2005, mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes, J Biol Chem, 28, 40406
  45. McGraw, 2009, The Akt kinases: isoform specificity in metabolism and cancer, Cell Cycle, 8, 2502, 10.4161/cc.8.16.9335 · DOI
  46. Tissenbaum, 2009, InAKTivation of insulin/IGF-1 signaling by dephosphorylation, Cell Cycle, 8, 3878, 10.4161/cc.8.23.10072 · DOI
  47. Slingerland, 2009, p27 as Jekyll and Hyde: regulation of cell cycle and cell motility, Cell Cycle, 8, 3455, 10.4161/cc.8.21.9789 · DOI
  48. Hoyland, 2005, Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes, Histol Histopathol, 2, 1327
  49. Mayo, 2009, PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells, Cell Cycle, 8, 896, 10.4161/cc.8.6.7899 · DOI
  50. Craig, 2004, MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol, Oncogene, 2, 5301
  51. Reusch, 2000, Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein, J Biol Chem, 27, 10761
  52. Blenis, 2007, RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates Cap-dependent translation, J Biol Chem, 28, 14056
  53. Sonenberg, 2006, The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity, EMBO J, 2, 2781
  54. Greenberg, 1997, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell, 9, 231
  55. Huang, 2008, Controlling the cell death mediators Bax and Bak: puzzles and conundrums, Cell Cycle, 7, 39, 10.4161/cc.7.1.5178 · DOI
  56. Coffer, 2000, Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1, Curr Biol, 1, 1201
  57. Howe, 2006, Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function, J Biol Chem, 28, 813
  58. Bonati, 2008, Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia, Leukemia, 2, 686
  59. Murtaugh, 2009, Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling, Cell Cycle, 8, 1860, 10.4161/cc.8.12.8744 · DOI
  60. Dean, 2010, Tumor initiation via loss of cell contact inhibition versus Ras mutation: do all roads lead to EMT?, Cell Cycle, 9, 897, 10.4161/cc.9.5.10933 · DOI
  61. Haluska, 2006, Examination of mutations in BRaf, NRas and PTEN in primary cutaneous melanoma, J Inv Dermatology, 12, 154
  62. Guidberg, 2007, The genome and epigenome of malignant melanoma, APMIS, 11, 1161
  63. Schnittger, 2006, Implications of NRAS mutations in AML: a study of 2502 patients, Blood, 10, 3847
  64. Koromilas, 2009, Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells, Cell Cycle, 8, 2070, 10.4161/cc.8.13.8891 · DOI
  65. Saito, 1999, Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia, Blood, 9, 3074
  66. Wittekind, 2003, Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma, Gut, 5, 706
  67. Liu, 2009, Epithelial ovarian cancer: focus on genetics and animal models, Cell Cycle, 8, 731, 10.4161/cc.8.5.7848 · DOI
  68. McCubrey, 2005, Analysis of BRAF mutation in primary and metastatic melanoma, Cell Cycle, 4, 1382, 10.4161/cc.4.10.2026 · DOI
  69. Söderkvist, 2004, Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas, Carcinogenesis, 2, 527
  70. Marais, 2004, Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 11, 855
  71. Ballotti, 2000, Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes, EMBO J, 1, 2900
  72. Kolch, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Mol Cell Biol, 2, 2262
  73. Marais, 2005, Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization, Mol Cell, 2, 963
  74. Spandidos, 2009, BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma, Cell Cycle, 8, 1402, 10.4161/cc.8.9.8308 · DOI
  75. Schimek, 2006, Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia, Cancer Res, 16, 3401
  76. Sill, 2009, Loss of Raf kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with c-RAF germline mutations, Leukemia, 2, 1049
  77. Rauen, 2006, Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome, Science, 31, 1287
  78. Bondeson, 2008, Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders, J Med Genet, 4, 500
  79. Xing, 2009, MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas, Cell Cycle, 8, 2122, 10.4161/cc.8.13.8710 · DOI
  80. Rudolph, 2007, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis, Gastroenterology, 13, 2557
  81. Castagnetta, 2002, Epidemiology, risk factors, and natural history of hepatocellular carcinoma, Ann N Y Acad Sci, 96, 13
  82. Tran, 2003, Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis, BMC Gastroenterol, 3, 19, 10.1186/1471-230X-3-19 · DOI
  83. Hayashi, 1998, Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma, Hepatology, 2, 951
  84. Kohno, 1998, Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering, Oncogene, 1, 57
  85. Aoyagi, 2004, Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma, Liver Int, 2, 432
  86. Thorgeirsson, 2006, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC, Gastroenterology, 13, 1117
  87. Guy, 2006, Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma, Cancer Res, 6, 2048
  88. Yano, 2006, Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors, Oncogene, 2, 6056
  89. Kim, 2006, Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells, Gastroenterology, 13, 1208
  90. Sebolt-Leopold, 2006, The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer, Neoplasia, 8, 1, 10.1593/neo.05373 · DOI
  91. Galle, 2008, Sorafenib in advanced hepatocellular carcinoma.-we have won a battle but not the war, J Hepatology, 4, 871, 10.1016/j.jhep.2008.09.001 · DOI
  92. Belghiti, 2004, Obesity and diabetes as a risk factor for hepatocellular carcinoma, Liver Transpl, 1, S69
  93. Anania, 2007, Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells, Cancer Res, 6, 2497
  94. Baba, 2008, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, J Hepatol, 4, 83
  95. Schneider, 1994, Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade, Proc Natl Acad Sci USA, 9, 10350
  96. Cho, 2004, Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway, Mol Cancer Res, 2, 159, 10.1158/1541-7786.159.2.3 · DOI
  97. Kim, 2004, Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential, FASEB J, 1, 1123
  98. Niepmann, 2009, Activation of hepatitis C virus translation by a liver-specific microRNA, Cell Cycle, 8, 1473, 10.4161/cc.8.10.8349 · DOI
  99. Yu, 2009, Targeting mTOR globally in cancer: thinking beyond rapamycin, Cell Cycle, 8, 3831, 10.4161/cc.8.23.10070 · DOI
  100. Yu, 2009, Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells, Cell Cycle, 8, 1567, 10.4161/cc.8.10.8489 · DOI
  101. Markowitz, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 30, 554
  102. Amzel, 2008, Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha, Cell Cycle, 7, 1151, 10.4161/cc.7.9.5817 · DOI
  103. Lee, 2005, PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas, Oncogene, 2, 1477, 10.1038/sj.onc.1208304 · DOI
  104. Gray, 1999, PIK3CA is implicated as an oncogene in ovarian cancer, Nat Genet, 2, 99
  105. Libra, 2009, PIK3CA mutations in human solid tumors, Cell Cycle, 8, 1352, 10.4161/cc.8.9.8255 · DOI · Paper page
  106. Thorgeirsson, 2007, Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma, J Clin Invest, 11, 2713
  107. McCubrey, 2004, The complexity of PTEN: mutation, marker and potential target for therapeutic intervention, Expert Opinion Ther Targets, 8, 537, 10.1517/14728222.8.6.537 · DOI
  108. Boyd, 1997, Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas, Cancer Res, 5, 3657
  109. Krolewski, 1998, Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus, Genes Chromosome Can, 2, 166
  110. Milde-Langosch, 2001, PTEN expression in breast and endometrial cancer: correlation with steroid hormone receptor status, Pathobiology, 6, 136
  111. Sasaki, 2008, Portrait of PTEN: messages from mutant mice, Cancer Sci, 9, 209
  112. Tsou, 1999, PTEN/MMAC1 mutations in hepatocellular carcinomas, Oncogene, 1, 3181
  113. Chang, 2000, Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma, Cancer Invest, 1, 123
  114. Emi, 1999, PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors, Jpn J Cancer Res, 9, 413
  115. Monden, 2000, PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas, Jpn J Cancer Res, 9, 287
  116. Li, 2007, Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma, Hepatol Res, 3, 389
  117. Nagasue, 2002, Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase, Int J Cancer, 10, 152
  118. Tai, 2007, Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection, Oncol Rep, 1, 1417
  119. Kim, 2003, Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells, Cancer Res, 6, 3453
  120. Lee, 2006, PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells, Virus Res, 12, 53
  121. Marais, 2009, Oncogenic Braf induces melanocyte senescence and melanoma in mice, Cancer Cell, 1, 294
  122. Bosenberg, 2009, Braf(V600E) cooperates with PTEN loss to induce metastatic melanoma, Nat Genet, 4, 544
  123. Dalla-Favera, 1999, Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas, Genes Chromosomes Cancer, 2, 322
  124. Raffeld, 1998, PTEN gene alterations in lymphoid neoplasms, Blood, 9, 3410
  125. Bhatia, 2004, Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway, Biochem Biophys Res Commun, 32, 932
  126. Agarwal, 2007, Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia, Nat Med, 1, 1203
  127. Ferrando, 2008, The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia, Cell Cycle, 7, 965, 10.4161/cc.7.8.5753 · DOI
  128. Bonilla, 2004, Promoter methylation of the PTEN gene is a common molecular change in breast cancer, Genes Chromosomes Cancer, 4, 117
  129. Mori, 2005, Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast, Oncology, 6, 398
  130. Wang, 2008, MicroRNA expression profiling in human ovarian cancer: miR-274 induces cell survival and cisplatin resistance by targeting PTEN, Cancer Res, 6, 425
  131. Jücker, 2007, Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations, Gene Ther, 1, 699
  132. Testa, 1992, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas, Proc Natl Acad Sci USA, 8, 9267
  133. Lin, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 44, 439
  134. Pusztai, 2008, An integrative genomic and proteomic analysis of PIK3CA, PTEN and Akt mutations in breast cancer, Cancer Res, 6, 6084
  135. Benedetti Panici, 1995, Molecular alterations of the Akt oncogene in breast cancer, Int J Cancer, 6, 280
  136. Mills, 2008, A novel Akt3 mutation in melanoma tumours and cell lines, Brit J Cancer, 9, 1265
  137. O'Meara, 2007, Patterns of somatic mutation in human cancer genomes, Nature, 44, 153
  138. Li, 2006, Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis and patient survival, Cancer Res, 6, 9221
  139. Flørenes, 2005, Expression of activated Akt and PTEN in malignant melanomas: Relationship with clinical outcome, Am J Clin Pathol, 12, 528
  140. Testa, 2004, Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions, Carcinogenesis, 2, 2053
  141. O'Byrne, 2005, Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer, Clin Cancer Res, 1, 2930
  142. Testa, 2001, AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells, Cancer Res, 6, 589
  143. Asselin, 2004, Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway, Mol Cancer, 3, 7, 10.1186/1476-4598-3-7 · DOI
  144. Hedley, 2006, Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients, Exp Hematol, 3, 1183
  145. Khwaja, 2005, PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways, Leukemia, 1, 586
  146. Andreeff, 2005, Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia, Leukemia, 1, 1543
  147. Steelman, 2008, Targeting the Raf/MEK/ERK pathway with small molecule inhibitors, Current Opinion Investigational Drugs, 9, 614
  148. Nicoletti, 2010, Emerging MEK Inhibitors, Exp Opin Emerging Drugs, 1, 203
  149. Tai, 2003, Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma, Cancer, 9, 1929
  150. Lee, 2001, The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade, J Biol Chem, 27, 16969, 10.1074/jbc.M011263200 · DOI
  151. Beretta, 2005, Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication, J Virol, 7, 8742
  152. Hurst, 2009, Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer, Cancer Metastasis Rev, 2, 305
  153. Zimmer, 2003, Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs, Clin Exp Metastasis, 2, 265
  154. Graff, 2000, Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis, Anticancer Res, 2, 1343
  155. Menard, 2004, HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA, J Cell Physiol, 20, 82
  156. Anderson, 2010, A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways, Cell Cycle, 9, 1722, 10.4161/cc.9.9.11358 · DOI
  157. Lichtenstein, 2004, AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression, J Biol Chem, 27, 2737
  158. Mercurio, 2002, Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells, J Cell Biol, 15, 165
  159. Cordon-Cardo, 2000, Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone, Clin Cancer Res, 6, 1891
  160. Kirby, 2000, Molecular markers for predicting prostate cancer stage and survival, BJU Int, 6, 869
  161. Steiger, 2009, Myc's secret life without Max, Cell Cycle, 8, 3848, 10.4161/cc.8.23.10088 · DOI
  162. Larsson, 2010, Cdk2: a key regulator of the senescence control function of Myc, Aging, 2, 244, 10.18632/aging.100140 · DOI
  163. Timchenko, 2009, GSK3beta and aging liver, Aging, 1, 582, 10.18632/aging.100060 · DOI
  164. DePinho, 2009, mTORC1 signaling governs hematopoietic stem cell quiescence, Cell Cycle, 8, 1003, 10.4161/cc.8.7.8045 · DOI
  165. Cosma, 2009, Somatic cell reprogramming control: signaling pathway modulation versus transcription factor activities, Cell Cycle, 8, 1138, 10.4161/cc.8.8.8206 · DOI
  166. Couch, 2000, 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K and SIGma1B genes, Cancer Res, 6, 5371
  167. Kallioniemi, 2000, Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis, J Natl Cancer Inst, 9, 1252
  168. Sawyers, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc Natl Acad Sci USA, 9, 10314
  169. Dreisbach, 2001, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/− mice, Proc Natl Acad Sci USA, 9, 10320
  170. Huang, 2007, Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer, J Biol Chem, 28, 3571
  171. Abate-Shen, 2008, Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model, J Clin Invest, 11, 3051
  172. Nimer, 2009, The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior, Cell Cycle, 8, 3120, 10.4161/cc.8.19.9627 · DOI
  173. Ahmad, 2009, Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells, Cell Cycle, 8, 1478, 10.4161/cc.8.10.8408 · DOI
  174. Lowenstein, 2009, MiR-34, SIRT1 and p53: the feed back loop, Cell Cycle, 8, 712, 10.4161/cc.8.5.7753 · DOI
  175. Chen, 2010, Mechanism of p53 stabilization by ATM after DNA damage, Cell Cycle, 9, 472, 10.4161/cc.9.3.10556 · DOI
  176. Ren, 2010, The p53 response element and transcriptional repression, Cell Cycle, 9, 870, 10.4161/cc.9.5.10825 · DOI
  177. Ryan, 2010, p53-mediated induction of Noxa and p53AIP1 requires NFkappaB, Cell Cycle, 9, 947, 10.4161/cc.9.5.10872 · DOI
  178. Verma, 2010, Mdm2 and p53 are highly conserved from placozoans to man, Cell Cycle, 9, 540, 10.4161/cc.9.3.10516 · DOI
  179. Alman, 2010, Protecting the hedgerow: p53 and hedgehog pathway interactions, Cell Cycle, 9, 506, 10.4161/cc.9.3.10552 · DOI
  180. Kroemer, 2010, Defective autophagy control by the p53 rheostat in cancer, Cell Cycle, 9, 250, 10.4161/cc.9.2.10493 · DOI
  181. Moretti, 2009, Mitochondrial MDM4 (MDMX): an unpredicted role in the p53-mediated intrinsic apoptotic pathway, Cell Cycle, 8, 3854, 10.4161/cc.8.23.10089 · DOI
  182. Kim, 2009, A theoretical model for p53 dynamics: identifying optimal therapeutic strategy for its activation and stabilization, Cell Cycle, 8, 3707, 10.4161/cc.8.22.10023 · DOI
  183. Barton, 2009, Regulation of p53: TRIM24 enters the RING, Cell Cycle, 8, 3668, 10.4161/cc.8.22.9979 · DOI
  184. Evangelisti, 2008, Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance, Leukemia, 2, 2080
  185. Libra, 2007, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim Biophys Acta, 177, 1263
  186. Franklin, 2006, Reactive oxygen species-induced activation of the MAP kinase signaling pathway, Antioxidants & Redox Signaling, 8, 1745, 10.1089/ars.2006.8.1745 · DOI
  187. McCubrey, 2006, Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress, Antioxidants & Redox Signaling, 8, 1807, 10.1089/ars.2006.8.1807 · DOI
  188. Tyner, 2009, RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK, Cell Cycle, 8, 2728, 10.4161/cc.8.17.9389 · DOI
  189. Lin, 2010, Regulation of Akt signaling activation by ubiquitination, Cell Cycle, 9, 487
  190. Ceryak, 2009, AKT1 mediates bypass of the G1/S checkpoint after genotoxic stress in normal human cells, Cell Cycle, 8, 1589, 10.4161/cc.8.10.8547 · DOI
  191. Zhang, 2010, Skip the nucleus, AKT drives Skp2 and FOXO1 to the same place?, Cell Cycle, 9, 868, 10.4161/cc.9.5.11153 · DOI
  192. McCubrey, 2009, Targeting the leukemic stem cell-the holy grail of leukemia therapy, Leukemia, 2, 25
  193. Morrison, 2006, PTEN-dependence distinguishes haematopoietic stem cells from leukemia-initating cells, Nature, 44, 475
  194. Zhang, 2007, Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance, Proc Natl Acad Sci USA, 10, 16158
  195. Lin, 2009, Exploring Rak tyrosine kinase function in breast cancer, Cell Cycle, 8, 2360, 10.4161/cc.8.15.9264 · DOI
  196. Liu, 2009, Epithelial ovarian cancer: focus on genetics and animal models, Cell Cycle, 8, 731, 10.4161/cc.8.5.7848 · DOI
  197. Colucci, 2009, PI3K signaling in lymphocyte migration, Cell Cycle, 8, 3307, 10.4161/cc.8.20.9692 · DOI
  198. Skladonowski, 2009, Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models, Cell Cycle, 8, 3208, 10.4161/cc.8.19.9758 · DOI
  199. Lee, 2008, Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors, Cancer Res, 6, 3243
  200. Rich, 2009, The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype, Cell Cycle, 8, 3274, 10.4161/cc.8.20.9701 · DOI · Paper page

200 of 230 shown

Cited by

Sorted by citations

Metadata

Authors
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., Donia, M., Fagone, P., Malaponte, G., Nicoletti, F., Libra, M., Milella, M., Tafuri, A., Bonati, A., Bäsecke, J., Cocco, L., Evangelisti, C., Martelli, A. M., Montalto, G., Cervello, M., & McCubrey, J. A.
Affiliations
  • Department of Microbiology and Immunology, East Carolina University, Greenville, NC 27858, USA
  • Department of Physics, East Carolina University, Greenville, NC 27858, USA
  • Department of Medical Biochemistry, Jagiellonian University Medical College, Krakow, Poland
  • Department of Immunology, Instititue for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia
  • Department of Biomedical Sciences, University of Catania, Catania, Italy
  • Regina Elena Cancer Center, Rome 00144, Italy
  • University of Rome, La Sapienza, Department of Hematology-Oncology, Rome 99161, Italy
  • University Hospital of Parma, Unit of Hematology and Bone-Marrow Transplantation, Via Gramsi n.14, Parma 43100, Italy
  • Department of Medicine, University of Göttingen, Göttingen, Germany
  • Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore, Università di Bologna, Bologna, Italy
  • Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy
  • Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologia, Molecolare “Alberto Monroy”, Palermo, Italy
Venue
Aging
Publisher
Impact Journals, LLC
Published
2011-03-10
Volume
3
Issue
3
Pages
192-222
ISSN
1945-4589
DOI
10.18632/aging.100296
PMC
PMC3091517
Cited by
553
References
15
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review